To view the latest data, view 2020 Access & Savings Report

2019 Generic Drug and Biosimilars Access and Savings in the U.S. 


The 11th annual edition of AAM's Savings and Access Report quantifies how much money American patients and our health care system are saving because of generic and biosimilar alternatives to brand-name prescription and biologic medications. In 2018, generic savings totaled $293 billion. The "Case for Competition" in a nutshell: The presence in the market of FDA-approved safe and effective generic and biosimilar medicines saves more Americans more money every year.

Download Report

Download Fact Sheet



Filled in 2018

Hand with Prescription


Prescriptions filled
in the U.S. are
dispensed as generics


Generic share of
overall drug spending
in the U.S.


Generic prescriptions
filled at $20 or less





Avg. copay

Generic drugs generate competition and reduce overall drug spending.
- The Pew Charitable Trusts

“The good news is that cheaper biotech drugs are coming. Known as biosimilars, these complex copycat drugs (which are a bit like generics) have been allowed in Europe since 2004 and in America since 2010. At first, owing to policy roadblocks and anti-competitive tactics by incumbents, only a few came to market. But the firms that make them, which range from biotech giants to scrappy upstarts, are turning the trickle into a torrent.” --The Economist, 2018

Patient savings case study:

Jonnie – Heart Disease Patient, Oklahoma

Jonnie of Skiatook, OK, manages her heart condition with metoprolol ER, the generic form of the brand-name drug Toprol XL. Metoprolol costs around $6, which is 81 percent less than the average retail price of $33.10 for the brand. On the other hand, there is no generic of the estrogen replacement she takes, and what she pays for the brand product equals her car payment.


Generic medications help
keep me healthy.



Generic drug
savings in the
U.S. 2018

Hand holding piggybank
10-year (2009-2018) savings: $2 trillion


Medicare Savings

($2,254 per enrollee)


Medicaid Savings

($817 per enrollee)

23 biosimilars have been approved in the U.S. to date and 9 are on the market. Biosimilars could lead to more than $54 billion in savings over the next ten years, giving 1.2 million patients access to needed medicines.

The U.S. drug supply chain remains one of the safest in the world.
Food and Drug Administration (FDA)
State-By-State Savings

Our Interactive Savings Map

In 2018, the per-state average savings realized by using generic prescription drugs was $5.7 billion. To view a full break down of generic savings by state and payer type, choose a state in the drop-down menu to download a one-page summary of how much that state saved from generic medicines.

Please note: state savings totals are rounded from actual totals.

Read Blog

Savings by Condition

Fact Sheets: Savings by Patient Condition

When patients and providers opt for generic and biosimilar alternatives instead of brand-name prescription and biologic medications, the savings really add up—for any condition being treated. We also compiled data for common co-morbidities of each of these conditions.

Take Action

Send a message to your lawmaker to
protect your generic savings.
Act Now


Find out how to fix the U.S.-Mexico-Canada Agreement (USMCA).


Share this page now:

Data source: IQVIA 2019, biosimilars as of 7/23/19

Association for Accessible Medicines


Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.